Home Science > Pipeline

Pipeline

Where there’s a will, there’s a way. Patients are our will.

Pipeline

PRE-CLINICAL
Undisclosed targets
Neuroscience
CombiPlex
Exploratory activities

JZP-341 (Long-acting Erwinia asparaginase)2
ALL/other hematological malignancies

Recombinant Pegaspargase1
Hematological malignancies

Pan-RAF Inhibitor program
Raf & Ras mutant tumors
Undisclosed targets
Ras/Raf/MAP kinase pathway2
Exosome targets (NRAS, STAT3 and 3 others)2
Hematological malignancies/solid tumors

Defibrotide
Exploratory activities

PHASE 1
JZP-324
Oxybate extended-release formulation
CPX-351
Low Intensity Dosing for higher risk MDS3

CPX-351 + other approved therapies
  • R/R AML or HMA Failure MDS3
  • First-line, fit AML (Phase 1b)
  • Low Intensity Therapy for first-line, unfit AML (Phase 1b)

PHASE 2
JZP-3854
Essential tremor (Phase 2b)

JZP-1504
PTSD
Defibrotide
  • Prevention of CAR-T associated neurotoxicity
CPX-351
  • HR-MDS (EMSCO)5
  • Newly diagnosed older adults with HR-AML4,5
CPX-351 + venetoclax
de novo or R/R AML3

PHASE 3
CPX-351
  • AML or HR-MDS >60 yrs (AML18)5
  • AML or HR-MDS >18 yrs (AML19)5
  • Newly diagnosed adults with standard- and HR-AML (AMLSG)5
  • Newly diagnosed <22 yrs with AML (COG)5
REGULATORY
JZP-258
Idiopathic hypersomnia

JZP-458 (recombinant Erwinia asparaginase)
ALL/LBL (pivotal Phase 2/3)

Neuroscience
Hematology/Oncology
1Opt-in opportunity
2Partnered collaboration
3Jazz & MD Anderson Cancer Center collaboration study
4Planned
5Cooperative group study
6Exclusive U.S. license
*PF-04457845

Molecule
Phase

JZP-258

  • EDS in Idiopathic Hypersomnia
3

Oral solution that contains a mixture of oxybate salts, resulting in 90 percent less sodium content than Xyrem® (sodium oxybate) oral solution. For Xyrem full Prescribing Information, including Boxed WARNING, please visit www.jazzpharma.com/medicines/our-medicines.

Clinicaltrials.gov

Lurbinectedin

  • Relapsed SCLC (ATLANTIS)
3

JZP-458

  • Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL)
2/3

Recombinant Erwinia asparaginase; granted Fast Track designation by the U.S. Food and Drug Administration in October 2019

Status – Pivotal Phase 2/3 study began enrollment 4Q19

Clinicaltrials.gov

CPX-351

  • AML or HR-MDS >60 yrs (AML18)
3
  • AML or HR-MDS >18 yrs (AML19)
3
  • Newly diagnosed adults with standard- and HR-AML (AMLSG)
3
  • Newly diagnosed <22 yrs with AML (COG)
3
  • HR-MDS (EMSCO)
2

  • Newly diagnosed older adults with HRAML
2

  • Low Intensity Dosing for higher risk MDS
1
Status – AML18, AML19, MDS and the R/R AML trial are key cooperative group studies

Study Sponsor – Cardiff University (for AML18, AML19)

Clinicaltrials.gov

For Vyxeos® (daunorubicin and cytarabine) full Prescribing Information, including Boxed WARNING, please visit www.jazzpharma.com/medicines/our-medicines

CPX-351 + venetoclax

  • De novo AML
2

  • Relapsed refractory AML
2

Jazz and MD Anderson Cancer Center Collaboration Study

Study Sponsor – MD Anderson Cancer Center

CPX-351 + gemtuzumab

  • Relapsed refractory AML (ages ≥18)
1

  • HMA Failure MDS (ages ≥18)
1

Jazz and MD Anderson Cancer Center Collaboration Study

Study Sponsor – MD Anderson Cancer Center

CPX-351 + various targeted agents

  • First-line, fit AML
1

JZP-385

  • Essential tremor (Phase 2b)
2

FAAH inhibitor PF-04457845

  • PTSD
2

Defibrotide

  • Prevention of CAR-T associated neurotoxicity
2

  • Exploratory activities
Pre-clinical

Defibrotide has orphan drug designation from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the prevention of hepatic VOD. Defibrotide has orphan drug designation from EMA for the prevention of acute GvHD.

Status – prevention of CAR-T associated neurotoxicity began enrollment 4Q19

Clinicaltrials.gov

For Defitelio® full Prescribing Information, please visit www.jazzpharma.com/medicines/our-medicines.

IMGN632

  • Hematologic malignancies*
1

*including AML and BPDCN
Opt-in opportunity through ImmunoGen collaboration

IMGN632 +/- venetoclax/azacitidine

  • CD123-positive AML
1

CombiPlex

  • Solid tumors
Pre-clinical

Exosome NRAS

  • Hematologic malignancies
Pre-clinical

Jazz & Codiak BioSciences collaboration

Exosome STAT3

  • Hematologic malignancies
Pre-clinical

Jazz & Codiak BioSciences collaboration

Exosome candidates

  • Solid tumors/Hematological malignancies
Pre-clinical

Jazz & Codiak BioSciences collaboration

Recombinant Pegaspargase

  • Hematologic malignancies
Pre-clinical

Opt-in based on Pfenex partnership

JZP-341

  • ALL/other hematologic malignancies
Pre-clinical

Long-acting Erwinia asparaginase; Opt-in based on Pfenex partnership

Pan-RAF Inhibitor Program

  • RAF & RAS mutant tumors
Pre-clinical